Modified base aptamer for specifically targeting osteoarthritis synovial cells and application of modified base aptamer
A technology for osteoarthritis and synoviocytes, applied in the field of modified base aptamers, can solve the problems of uncertain binding force, inability to prove specificity, inapplicability to OA synoviocytes, etc., to reduce cumbersome steps, The screening process is simple and the effect of specificity enhancement
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] Example 1 Screening of Osteoarthritis Synoviocyte Aptamers
[0027] Step 1. Preparation of oligonucleotide library:
[0028] The oligonucleotide library is derived from the X-Aptamer kit (AM Biotechnologies, USA), which includes a microsphere library specially designed and produced by the American AM Biotech Company. The storage capacity is generally 109 microspheres. Magnetic control of particles to screen for high-affinity modified aptamers.
[0029]X-Aptamer high-affinity modified aptamers contain modified oligonucleotides, which can bind to specific cells, proteins or small molecule targets with high affinity and strong specificity. It is very different from traditional nucleic acid aptamer screening in that its library is designed by computer and contains a series of novel chemically modified nucleotides. These novel chemical modifications enhance the affinity of nucleotides to targets and the stability of aptamers, and increase the efficiency of screening. Thes...
Embodiment 2
[0045] Example 2 Sequencing and structural analysis of aptamers
[0046] PCR amplification
[0047] PCR amplification was performed on the supernatant. Forward primer: one 1.5mL centrifuge tube: 5’-CAG GGG ACG CAC CAAGG-3’, reverse primer: 5’-ATC ACG CAG CAC GCG GGT CAT GG-3’, store at -20°C. The PCR reaction uses 100 μL of 1×PCR buffer (2.5mM MgCl2, 0.2mM dNTP, 0.4μM forward primer, 0.4μM reverse primer and 1U Taq Polymerase), the amplification conditions are: pre-denaturation 94°C, 1min, cycle conditions 94°C for 30s, 50°C for 30s and 72°C for 1min, and finally 72°C for 3min. Set for 20 loops.
[0048] next generation sequencing
[0049] Send the PCR products obtained above to Sangon Bioengineering (Shanghai) Co., Ltd. for next-generation sequencing analysis. After analysis, the 2 most frequently sequenced aptamers were synthesized against synoviocytes.
[0050] The next generation sequencing results are:
[0051] SA1:TTTTTAACACGACAACGCYGTGACXCXCGAACGYCATGCCGGTGGGCCCA...
Embodiment 3
[0054] Example 3 Affinity Verification of Aptamers
[0055] Cell preparation: Human primary osteoarthritic synoviocytes were passaged at 37°C, 5% CO 2 Culture in medium for 1 to 2 days, so that it is in the logarithmic growth phase, and let the cells cover about 90%-95% of the bottom area of the culture dish, and at the same time ensure that the cells have good viability. ) was washed three times, and 1 mL of buffer A was added to incubate for 10 minutes.
[0056] Incubation process: select cells in the logarithmic growth phase, digest with 0.25% trypsin, take an appropriate amount of cell suspension, wash with binding buffer twice, add fluorescent markers with a concentration of 300nmol / L and a volume of 0.2mL The aptamer library and the two aptamers (SA1, SA2) sequenced in Example 2 were placed on ice, protected from light, and incubated on a shaker for 30 minutes. After the incubation, the cells were washed 3 times with buffer B;
[0057] Loss analysis: add 0.2mL buffer...
PUM

Abstract
Description
Claims
Application Information

- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com